Extra Caution Needed In Uncertain Period For Off-label Info Distribution
This article was originally published in The Pink Sheet Daily
In off-label promotion investigations, OIG looks for kickback issues or other bad conduct and whether there is patient harm.
You may also be interested in...
BOSTON-Pfizer's new Medicine Safety Web site is the first attempt by a pharmaceutical company to reclaim authority over risk communication from FDA
FDA has at least 16 projects under way to improve its information technology systems and infrastructure, but no comprehensive IT strategic plan to coordinate and manage the efforts, according to the Government Accountability Office